Sutton Wealth Advisors Inc. Xencor Inc Transaction History

Sutton Wealth Advisors Inc.

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 Nov 07, 2023	SELL	$25.95 - $36.95 $24,496 - $34,880	-944 Closed	0 $0
Q3 2022 Nov 07, 2023	SELL	$24.62 - $32.44 $24 - $32	-1 Reduced 0.11%	944 $24.5 Million
Q2 2022 Nov 07, 2023	BUY	$19.74 - $29.01 $11,646 - $17,115	590 Added 166.2%	945 $25.9 Million
Q1 2022 Nov 07, 2023	SELL	$26.68 - $41.63 $16,968 - $26,476	-636 Reduced 64.18%	355 $9.47 Million
Q4 2021 Nov 07, 2023	BUY	$33.67 - $43.44 $1,952 - $2,519	58 Added 6.22%	991 $39.8 Million
Q3 2021 Nov 07, 2023	BUY	$30.65 - $35.68 $7,478 - $8,705	244 Added 35.41%	933 $30.5 Million
Q2 2021 Nov 07, 2023	SELL	$34.33 - $44.68 $4,874 - $6,344	-142 Reduced 17.09%	689 $23.8 Million
Q3 2020 Nov 07, 2023	BUY	$30.09 - $43.02 $14,443 - $20,649	480 Added 136.75%	831 $32.2 Million
Q2 2020 Nov 07, 2023	BUY	$27.76 - $33.42 $5,191 - $6,249	187 Added 114.02%	351 $11.4 Million
Q1 2020 Nov 07, 2023	SELL	$20.69 - $37.79 $7,779 - $14,209	-376 Reduced 69.63%	164 $4.9 Million
Q4 2019 Nov 07, 2023	BUY	$32.75 - $41.43 $17,685 - $22,372	540 New	540 $18.6 Million

215

71.5M

2.5K

7.9K

Ticker XNCR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,698,100
Market Cap $1.43B
Description
Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal ...

Get notified when there are updates to the investment portfolio of Sutton Wealth Advisors Inc., based on Form 13F filings with the SEC.

Stay updated on Sutton Wealth Advisors Inc. with notifications on news.